Clinical Trial Search

Primary: Number of Patients With Progression-free Survival at 2 Years — 19 Participants

Primary: Percentage of Participants With >=50% Improvement From Baseline in Clinical Global Impression for Bipolar Disorders Overall Severity — 37; 21 percentage of participants

Primary: Percent Change in Delayed Recall at 4 Months as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R) — 7.0 percent change — p=<0.001

Primary: Change From Baseline Levine Symptom Severity Scale Status at Weeks 6, 12,18. — 0.4; -3.2; -4.2; -9.4 Scores on a scale

Primary: Change From Baseline in Mean Systolic Blood Pressure (MSBP) at Week 6 Endpoint — -1.2; -9.2; -6.9; -7.8 mmHg — p=0.0096

Primary: Coronary Flow Reserve (CFR) — 1.77 ratio: peak to baseline CFV

Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1 — 68.35; 71.33 percentage of participants

Primary: The Percentage of Subjects Who Pass the 20gm Peanut Flour (~50% Peanut Protein) Oral Food Challenge 2-4 Weeks After Discontinuing Peanut OIT Therapy — 3; 1 Participants

Primary: Percentage of Participants With a Cardiac Output Within and Outside 20% of Baseline Values — 71; 66; 29; 34 percentage of patients — p=0.37

Primary: Anti-glycoprotein E (Anti-gE) Antibody (Ab) Concentrations — 50522.9; 48589.4 mIU/mL

Primary: Safety of External-beam PBI Utilizing 40Gy in Ten Daily Fractions Over Two Weeks — 0; 0; 0; 0 Participants

Primary: Heart Rate — 96.7; 88 BPM

Primary: Exposure-adjusted Incidence Rate of Major or Clinically Relevant Non-major Bleeding Episode — 2.02; 10.1; 10.5; 14.6 Number of Patients per 100 Patient years — p=0.035

Primary: Percentage of Subjects Who Successfully Undergo Continuous Bedside Polysomnography for at Least 24 Hours. — 9; 8; 5 Participants

Primary: Percentage of Lenses Graded as 0 or 1 for Lens Centration at Day 14 — 100.0; 99.4 percentage of lenses